Amneal Launches First Two Respiratory Metered-Dose Inhalation Products in the U.S.

Rhea-AI Summary

Amneal (Nasdaq: AMRX) launched two metered-dose inhalation (MDI) generics in the U.S. on April 14, 2026: albuterol sulfate inhalation aerosol (90 mcg) and beclomethasone dipropionate HFA inhalation aerosol (40/80 mcg), both FDA-approved in 2025.

These are Amneal’s first U.S. MDI launches, manufactured at its dedicated inhalation facility in Ireland. According to IQVIA U.S. annual sales data, 12-month sales through Feb 2026 were about $1.5B for albuterol and $321M for beclomethasone, indicating meaningful market opportunity.

AI-generated analysis. Not financial advice.

Positive

• First U.S. MDI launches for Amneal, expanding respiratory portfolio
• Albuterol market ~ $1.5B (12 months ended Feb 2026)
• Beclomethasone market ~ $321M (12 months ended Feb 2026)
• Dedicated inhalation facility in Ireland for complex MDI manufacturing

Negative

• Beclomethasone not for acute relief—limited to maintenance therapy
• Common adverse reactions reported for both products (headache, pharyngitis, rhinitis)

News Market Reaction – AMRX

+2.26%

1 alert

+2.26% News Effect

On the day this news was published, AMRX gained 2.26%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Albuterol dose: 90 mcg per actuation Beclomethasone doses: 40 mcg and 80 mcg per actuation Albuterol age indication: 4 years and older +4 more

7 metrics

Albuterol dose 90 mcg per actuation Albuterol sulfate inhalation aerosol strength

Beclomethasone doses 40 mcg and 80 mcg per actuation Beclomethasone dipropionate HFA inhalation aerosol strengths

Albuterol age indication 4 years and older Treatment or prevention of bronchospasm and exercise-induced bronchospasm

Beclomethasone age indication 5 years and older Maintenance treatment of asthma as prophylactic therapy

Adverse reaction threshold ≥3.0% Common adverse reactions with albuterol vs placebo

Albuterol market sales $1.5 billion IQVIA U.S. annual sales, 12 months ended Feb 2026

Beclomethasone market sales $321 million IQVIA U.S. annual sales, 12 months ended Feb 2026

Market Reality Check

Price: $12.43 Vol: Volume 1,490,233 vs 20-da...

normal vol

$12.43 Last Close

Volume Volume 1,490,233 vs 20-day average 1,863,861 (relative volume 0.8x). normal

Technical Shares at $12.83, trading above 200-day MA of $11.25 and 16.8% below 52-week high.

Peers on Argus

AMRX gained 2.31% while key peers also rose: PBH +1.37%, INDV +4.32%, BHC +2.88%...

AMRX gained 2.31% while key peers also rose: PBH +1.37%, INDV +4.32%, BHC +2.88%, HCM +1.26%, PRGO +6.6%. Scanner did not flag a sector-wide momentum move.

Historical Context

5 past events · Latest: Apr 09 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Apr 09	Generic launch	Positive	+0.7%	Launch of bimatoprost ophthalmic solution as generic to LUMIGAN.
Apr 07	Earnings date set	Neutral	+3.2%	Announcement of Q1 2026 earnings release and webcast timing.
Apr 07	Charitable donation	Neutral	-0.2%	$2 million donation to Parkinson’s patient assistance foundations.
Mar 05	Investor conference	Neutral	-0.1%	Participation in Barclays Global Healthcare Conference fireside chat.
Feb 27	Earnings results	Positive	-4.7%	Q4 and 2025 results with $3.02B revenue and positive GAAP net income.

Pattern Detected

Recent product launches and corporate events have generally seen modest, mostly aligned price reactions, with a notable divergence on the latest earnings release.

Recent Company History

This announcement adds two complex respiratory MDIs to Amneal’s portfolio, following the April 9, 2026 launch of bimatoprost ophthalmic solution supported by IQVIA sales of about $719 million. In early April, the company also scheduled its Q1 2026 earnings release and announced a $2 million Parkinson’s-related donation, both with limited price impact. A March investor conference update and the Q4 2025 earnings release, which reported $3.02 billion in 2025 revenue and positive GAAP net income, round out a pattern of steady operational and pipeline progress.

Market Pulse Summary

This announcement marks Amneal’s entry into complex respiratory MDIs with U.S. launches of generic v...

Analysis

This announcement marks Amneal’s entry into complex respiratory MDIs with U.S. launches of generic versions of PROAIR HFA and the original QVAR, targeting IQVIA U.S. markets of $1.5 billion and $321 million. It follows other recent launches and steady growth highlighted in prior results. Investors may watch upcoming earnings for quantitative contributions from these products, competitive responses in inhalation, and further pipeline updates in the respiratory platform.

Key Terms

metered-dose inhalation, mdi, bronchospasm, corticosteroid, +4 more

8 terms

metered-dose inhalation medical

"These are the Company’s first two metered-dose inhalation (MDI) product launches in the U.S."

A metered-dose inhalation is a drug-delivery method that releases a precise, pre-measured amount of medication as an inhaled spray or aerosol, typically from a handheld canister or inhaler. Think of it like a spray can that delivers the same short puff each time so the patient gets a consistent dose to the lungs. Investors care because the delivery method affects a drug’s effectiveness, safety profile, manufacturing complexity, regulatory approval, and market adoption, all of which influence revenue and risk.

mdi medical

"These are the Company’s first two metered-dose inhalation (MDI) product launches in the U.S."

A metered-dose inhaler (MDI) is a small, handheld device that sprays a measured amount of medicine directly into the lungs to treat breathing problems like asthma or other chronic lung conditions. Investors watch MDIs because regulatory approvals, manufacturing capacity, device patents and supply chain reliability determine whether a respiratory drug can be sold at scale; think of the MDI as the product’s delivery packaging — its quality and availability directly affect sales, costs and risk.

bronchospasm medical

"indicated for the treatment or prevention of bronchospasm in patients 4 years of age and older"

A bronchospasm is a sudden tightening of the muscles around the airways that narrows breathing passages and causes wheezing, coughing or shortness of breath — like squeezing a flexible straw until air struggles to pass. For investors, bronchospasm is important because it can signal a drug safety issue or side effect that affects clinical trial outcomes, regulatory decisions, product labeling and market acceptance, all of which can influence a company’s financial prospects.

corticosteroid medical

"Beclomethasone dipropionate HFA inhalation aerosol is a corticosteroid indicated for the maintenance treatment"

A corticosteroid is a class of prescription medicines that reduce inflammation and calm an overactive immune response, like turning down an overly sensitive alarm system in the body. Investors care because these drugs are common in treating many conditions, can drive sales or liability risks based on safety and regulatory decisions, and often affect the value of companies developing, manufacturing, or testing related therapies.

tachycardia medical

"adverse reactions... include headache, tachycardia, pain, dizziness, pharyngitis, and rhinitis."

An abnormally fast heart rate — when the heart is racing and may not fill or pump blood efficiently, similar to an engine revving too high. For investors, reports of tachycardia matter because they signal potential safety or effectiveness issues for drugs, devices or treatments, which can affect regulatory approval, product labeling, legal risk and market value.

pharyngitis medical

"adverse reactions... include headache, tachycardia, pain, dizziness, pharyngitis, and rhinitis."

Pharyngitis is inflammation or infection of the throat (pharynx) that commonly causes sore throat, difficulty swallowing and swollen glands; think of it as a throat cold that makes speaking and eating uncomfortable. Investors watch it because spikes or trends in throat infections can affect healthcare visits, drug and diagnostic sales, workplace absenteeism and insurance costs—similar to how flu patterns can shift demand and revenue in related industries.

rhinitis medical

"adverse reactions... include headache, tachycardia, pain, dizziness, pharyngitis, and rhinitis."

Rhinitis is inflammation of the nose lining that causes symptoms such as a runny or blocked nose, sneezing, and itching; it can be triggered by allergies, infections or irritants. For investors, rhinitis matters because it drives demand for over‑the‑counter and prescription nasal treatments, seasonal sales swings, and can affect workforce productivity and healthcare costs—much like a traffic jam in the nose that slows normal breathing and daily activity.

upper respiratory tract infection medical

"adverse reactions... include headache, pharyngitis, upper respiratory tract infection, rhinitis, increased asthma symptoms"

An upper respiratory tract infection is an illness that affects the nose, throat and windpipe—think of a common cold or sore throat—usually caused by viruses or sometimes bacteria. For investors it matters because widespread infections can reduce worker productivity, slow manufacturing or clinical trial timelines, change demand for healthcare products and services, and affect short‑term sales and costs in companies tied to medical care or consumer health, much like a temporary supply‑chain or staffing disruption.

AI-generated analysis. Not financial advice.

• Launch of albuterol sulfate inhalation aerosol and beclomethasone dipropionate HFA inhalation aerosol

BRIDGEWATER, N.J., April 14, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (Nasdaq: AMRX) today announced the U.S. launch of albuterol sulfate inhalation aerosol and beclomethasone dipropionate HFA inhalation aerosol, two widely prescribed respiratory products that were approved by the Food and Drug Administration (FDA) in 2025. These are the Company’s first two metered-dose inhalation (MDI) product launches in the U.S., marking Amneal’s entry into the complex inhalation category.

Albuterol sulfate inhalation aerosol (90 mcg per actuation) is a generic equivalent of PROAIR^® HFA. Beclomethasone dipropionate HFA inhalation aerosol (40 mcg and 80 mcg per actuation) is a generic equivalent of the original QVAR^® Inhalation Aerosol, 40 mcg and 80 mcg. Both products utilize the hand-breath actuator device in which the cannister is depressed by the patient before inhaling. This option was previously discontinued for QVAR^®, creating a potential gap in patient choice.

“The launch of these two important inhalation products marks a significant milestone for Amneal and underscores the continued expansion of our respiratory platform,” said Dr. Srinivas Kone, Senior Vice President and Chief Scientific Officer – Affordable Medicines. “Manufactured at our dedicated inhalation facility in Ireland, these complex products reflect our ability to develop and scale difficult-to-make formulations that address meaningful gaps in patient access. With multiple additional inhalation products in active development, we are building a durable and differentiated presence in this attractive category.”

Product Information

Albuterol Sulfate Inhalation Aerosol is indicated for the treatment or prevention of bronchospasm in patients 4 years of age and older with reversible obstructive airway disease, and for the prevention of exercise-induced bronchospasm in patients 4 years of age and older.

The most common adverse reactions reported with the use of albuterol sulfate inhalation aerosol (≥3.0% and greater than placebo) include headache, tachycardia, pain, dizziness, pharyngitis, and rhinitis. For full prescribing information, see package insert here.

Beclomethasone dipropionate HFA inhalation aerosol is a corticosteroid indicated for the maintenance treatment of asthma as prophylactic therapy in patients 5 years of age and older. It is not indicated for the relief of acute bronchospasm.

The most common adverse reactions reported with the use of beclomethasone dipropionate HFA inhalation aerosol include headache, pharyngitis, upper respiratory tract infection, rhinitis, increased asthma symptoms, and sinusitis. For full prescribing information, please refer to the package insert here.

According to IQVIA^® U.S. annual sales data, for the 12 months ended February 2026, albuterol sulfate inhalation aerosol had sales of approximately $1.5 billion, and beclomethasone dipropionate HFA inhalation aerosol had sales of approximately $321 million.

All trademarks are property of their respective owners.

About Amneal
Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX), headquartered in Bridgewater, New Jersey, is a diversified, global biopharmaceutical leader focused on expanding access to affordable and innovative medicines. Founded in 2002 by brothers and co-CEOs Chirag and Chintu Patel, Amneal was built on the belief that innovation only matters if it’s accessible. Today, Amneal has a diverse and growing portfolio of approximately 300 complex generic, specialty and biosimilar medicines, delivering over 160 million prescriptions each year, primarily in the United States. Our Affordable Medicines segment spans retail generics, injectables, and biosimilars. Our Specialty segment provides branded treatments in neurology, including Parkinson’s disease and migraine, and endocrinology. Our AvKARE segment distributes pharmaceuticals and medical products to U.S. federal, retail, and institutional customers. For more, please visit www.amneal.com and follow us on LinkedIn.

Cautionary Statement on Forward-Looking Statements
Certain statements contained herein, regarding matters that are not historical facts, may be forward-looking statements (as defined in the U.S. Private Securities Litigation Reform Act of 1995). Such forward-looking statements include statements regarding management’s intentions, plans, beliefs, expectations, financial results, or forecasts for the future, including among other things: discussions of future operations; expected or estimated operating results and financial performance; and statements regarding our positioning, including our ability to drive sustainable long-term growth, and other non-historical statements. Words such as “plans,” “expects,” “will,” “anticipates,” “estimates,” and similar words, or the negatives thereof, are intended to identify estimates and forward-looking statements. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company’s filings with the Securities and Exchange Commission, including under Item 1A, “Risk Factors” in the Company’s most recent Annual Report on Form 10-K and in its subsequent reports on Forms 10-Q and 8-K. Forward-looking statements included herein speak only as of the date hereof and we undertake no obligation to revise or update such statements to reflect the occurrence of events or circumstances after the date hereof.

Investor Contact
Anthony DiMeo
VP, Investor Relations
anthony.dimeo@amneal.com

Media Contact
Brandon Skop
Sr. Director, Corporate Communications
brandon.skop@amneal.com

FAQ

What did Amneal (AMRX) announce on April 14, 2026 about MDI product launches?

Amneal launched two MDI generics: albuterol 90 mcg and beclomethasone 40/80 mcg in the U.S. According to the company, both were FDA-approved in 2025 and represent its first U.S. metered-dose inhalation product launches, manufactured at its Ireland facility.

How large are the U.S. markets for the albuterol and beclomethasone products Amneal (AMRX) launched?

Albuterol had approximately $1.5 billion in U.S. annual sales; beclomethasone about $321 million. According to the company, these IQVIA figures cover the 12 months ended February 2026, indicating sizable addressable markets.

What are the clinical indications and age ranges for Amneal's new albuterol and beclomethasone inhalers?

Albuterol is indicated for bronchospasm treatment or prevention in patients aged 4 and older; beclomethasone is maintenance therapy for asthma in patients 5 and older. According to the company, beclomethasone is not for relief of acute bronchospasm.

Do Amneal's new inhalation products use the same actuator as prior branded options like QVAR or PROAIR?

Yes. Both products use the hand-breath actuator where the canister is depressed before inhaling. According to the company, that actuator option had been discontinued for QVAR, creating a potential patient choice gap.

Where are Amneal's new MDI products manufactured and what does that mean for scale?

Amneal manufactures these complex MDIs at its dedicated inhalation facility in Ireland. According to the company, the facility supports development and scale of difficult-to-make inhalation formulations and additional inhalation programs are in development.